Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy

Blood

Volumn 94, Issue 1, 1999, Pages 52-61

  Moscow, Jeffrey A ^b   Huang, Hui ^b   Carter, Charles ^b   Hines, Kenneth ^b   Zujewski, JoAnne ^b   Cusack, Georgie ^b   Chow, Cathy ^b   Venzon, David ^b   Sorrentino, Brian ^b   Chiang, Yawen ^b   Goldspiel, Barry ^b   Leitman, Susan ^b   Read, Elizabeth J ^b   Abati, Andrea ^b   Gottesman, Michael M ^b   Pastan, Ira ^b   Sellers, Stephanie ^b   Dunbar, Cynthia ^b   Cowan, Kenneth H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; GENE PRODUCT; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; VIRUS VECTOR;

ARTICLE; BONE MARROW; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; GENE THERAPY; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MARKER GENE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STEM CELL;

EID: 0033168346     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.1.52.413k35_52_61     Document Type: Article

References (31)

1. Deisseroth AB, Pizzomo G: The use of chemotherapy resistance gene in cancer treatment. Cancer J Sci Am 3:60, 1997
2. Licht T, Herrmann F, Gottesman MM, Pastan I: In vivo drug-selectable genes: A new concept in gene therapy. Stem Cells 15:104, 1997
3. Banerjee D, Zhao SC, Li M-X, Scweitzer BI, Mineishi S, Bertino JR: Gene therapy using drug resistance genes: A review. Stem Cells 12:378, 1994
4. Gros P, Ben Neriah Y, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers drug resistance. Nature 323:728, 1986
5. Ueda K, Carderelli C, Gottesman M, Pastan I: Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84:3004, 1987
6. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I: Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 88:547, 1991
7. Sorrentino B, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257:99, 1992
8. Podda S, Ward M, Himelstein A, Richardson C, Dela Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 89:9676, 1992
9. Richardson C, Bank A: Preselection of transduced murine hematopoietic stem cell populations leads to increased long-term stability and expression of the human multiple drug resistance gene. Blood 86:2579, 1995
10. Hanania EG, Fu S, Roninson I, Zu Z, Gottesman MM, Deisseroth AB: Resistance to taxol chemoherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther 2:279, 1995
11. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A, Antman K: Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy in autologous stem-cell transplantation. J Clin Oncol 16:165, 1998
12. Hanania EG, Giles RE, Kavanagh J, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holtzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andreeff M, Champlin R, Deisseroth AB: Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 93:15346, 1996
13. Cowan KH, Moscow JA, Huang H, Zujewski J, O'Shaughnessy J, B. Sorrentino, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinber SG, Wilson WW, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis AW: Paclitaxel chemotherapy following autologous stem cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance cDNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999 (in press)
14. Peters SO, Kittler ELW, Ramshaw HS, Quesenberry PJ: Ex-vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 87:30, 1996
15. Emmons RVB, Doren S, Zujewski J, Cottler-Fox M, Carter CS, Hines K, O'Shaughnessy JA, Leitman SF, Cowan KH, Dunbar CE: Retroviral gene transduction of adult peripheral blood or marrow decreased CD34+ cells for 6 hours without growth factors or an autologous stroma does not improve marking efficiency assessed in vivo. Blood 89:4040, 1997
16. + marrow cells in patients with breast cancer or neuroblastoma. Blood 77:1717, 1991
17. Chen C-j, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB: Genomic organization of the human multidrug resistance (MDR1) gene and origins of p-glycoproteins. J Biol Chem 265:506, 1990
18. Sorrentino BP, McDonagh KT, Woods D, Orlic D: Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood 86:491, 1995
19. +-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85:3048, 1995
20. Cornetta K, Morgan RA, Anderson WF: Safety issues related to retroviral gene transfer to humans. Hum Gene Ther 2:5, 1991
21. Kittler ELW, Peters SO, Crittenden RB, Debatis ME, Ramshaw HS, Stewart FM, Quesenberry PJ: Cytokine-facilitated transduction leads to low-level engraftment in nonablated hosts. Blood 90:865, 1997
22. Tisdale JF, Hanazono Y, Seller SE, Agricola BA, Metzger ME, Donahue RE, Dunbar CE: Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 92:1131, 1998
23. Blau CA, Neff T, Papayannopoulou T: Cytokine prestimulation as a gene therapy strategy: Implications for using the MDR1 gene as a dominant selectable marker. Blood 89:146, 1996
24. Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP: Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo expansion, but these grafts cause a myeloproliferative syndrome in transplanted mice. Blood 92:2269, 1998
25. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD: Human Mdr 1 protein overexpresson delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36:507, 1997
26. Bezombes C, Maestre N, Laurent G, Levade T, Bettaib A, Jaffrezou JP: Restoration of TNF-alpha-induced ceramide generation in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC388. FASEB J 12:101, 1998
27. Hanania EG, Deisseroth AB: Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1:21, 1994
28. Brenner MK, Rill DR, Holladday MS: Gene marking to determine whether autologous marrow infusion restores long term haemopoiesis in cancer patients. Lancet 342:1134, 1993
29. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RCJ, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132, 1993
30. Bonadonna G, Zambetti M, Valagussa P: Doxorubicin and CMF regimens in breast cancer with more than 3 positive nodes. 10 year results. JAMA 273:542, 1995
31. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil, and leucovorin to flourouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 7:1437, 1989